Mr. Ric Rumble reports

TSO3 CLOSES C$11,500,000 BOUGHT DEAL OFFERING

TSO3 Inc. has completed its previously announced public offering of 9.2 million units at a price of $1.25 per unit for aggregate gross proceeds to TSO3 of $11.5-million. The offering was completed on a bought-deal basis through a syndicate of underwriters co-led by Desjardins Capital Markets and Canaccord Genuity, and including Euro Pacific Canada Inc. and Laurentian Bank Securities Inc. Each unit comprises one common share and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share of TSO3 at a price of $1.875 per common share at any time until March 5, 2017. The warrants are subject to an accelerated expiry if, at any time after Sept. 30, 2015, the closing trade price of the common shares on the Toronto Stock Exchange is equal or superior to $2.00 for any 10 consecutive trading days.

This offering was made through a short-form prospectus filed in all provinces of Canada. The common shares being issued pursuant to the offering have been approved for listing on the Toronto Stock Exchange. Following the closing of the offering, there are 82,599,656 common shares of TSO3 issued and outstanding.

As the company recently obtained U.S. regulatory clearance for the Sterizone VP4 sterilizer, net proceeds from the offering will be used to strengthen the company's financial position in support of a channel partner activity, ramp-up working capital to support sales and for general corporate purposes.

We seek Safe Harbor.